Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations.
Cohen AK, Jaudon TW, Schurman EM, Kava L, Vogel JM, Haas-Godsil J, Lewis D, Crausman S, Leslie K, Bligh SC, Lizars G, Davids JD, Sran S, Peluso MJ, McCorkell L.
Cohen AK, et al.
Res Sq [Preprint]. 2023 Sep 20:rs.3.rs-3359429. doi: 10.21203/rs.3.rs-3359429/v1.
Res Sq. 2023.
PMID: 37790297
Free PMC article.
Preprint.